📌 Key Takeaways
- Topic: Silicon Metal vs Silica: Production Process and Key Differences
- Keywords: Evonik Aerosil
- Published: 2026-11-20 10:33:19
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
What Is Silica Slurry? Composition, Types and Uses in Polishing
- Porous Silica: Types, Pore Structure and Applications in Adsorption and Catalysis
- Silica Manufacturer in China: How to Evaluate Quality, Capacity and Export Experience
- Mesoporous carriers also offer an attractive alternative in the oral therapy of macromolecules rather than the more complicated parenteral administration. Peptides and proteins may denature in the greatly acidic environment of the stomach, lose their structure and function [ 1, 13 ], while the proteases in the digestive system break down the protein chains, making the molecule useless and the therapy ineffective [ 1, 13, 91 ]. Additionally, poor permeation through the epithelium is another hindering component during the oral administration of macromolecules [ 1, 13 ]. The macromolecule locked inside the pores stays protected against enzymatic or chemical degradation, and its permeation through the epithelium can also be improved [ 1, 13, 91 ]. It is also true that smaller pores deliver better protection for macromolecules against degradation [ 1 ]. Mesoporous silica nanocarriers have extra intriguing advantages because of their special properties that make them outstanding over other carriers and therefore provide a popular alternative in formulating macromolecules [ 1, 13 ].
- Aerosil 200: Specifications, Applications and Equivalent Fumed Silica Grades
- Thermal Conductive Filler: Silica vs Alumina vs Boron Nitride Compared
- Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
Silica Testing Methods: How to Test Purity, Particle Size, BET and Moisture
What is silica (SiO₂)?
barium sulfate 16. Izquierdo-Barba I., Martinez Á., Doadrio A.L., Pérez-Pariente J., Vallet-Regí M. Release evaluation of drugs from ordered three-dimensional silica structures. Eur. J. Pharm. Sci. 2005;26:365-373. doi: 10.1016/j.ejps.2005.06.009. [ DOI ] [ PubMed ] [ Google Scholar ]
What is the difference between fumed silica and precipitated silica?
silica for sale Targeted therapy, aiming, for instance, at antitumor treatments, can be divided into active and passive forms [ 72, 73 ]. Passive targeting is based on higher vascularity and higher vascular permeability of the tumor, as well as inflamed tissues, compared to physiological ones [ 73, 74 ]. Additionally, the lymphatic circulation of the tumor shows decreased efficiency [ 25 ], which led to easier accumulation of nanoparticles in the tumor or inflamed tissues [ 10, 27, 72, 74 ]. This passive accumulation is normally called "ELVIS" (Extravasation through Leaky Vasculature and later Inflammatory cell-mediated Sequestration) [ 72, 74 ]. From the facet of surface qualities, negatively charged nanoparticles accumulate less effectively inside cells, due to the negatively charged cell membrane, which slows down the cellular uptake, so, in this case, a neutral surface charge is more favorable [ 25 ]. In contrast, active targeting can be accomplished by functionalizing the outer surface of the silica carriers [ 10, 27, 72 ], where molecules are attached to the surface of the carriers that specifically bind to certain cell surface ligands and receptors, which are characteristic of tumor-, but not of healthy cells. This selective method provides more effective treatment and reduces the side impacts of cytotoxic APIs on healthy cells and tissues [ 10, 27 ]. The most recent findings on active targeting possibilities are summarized in Table 3. García-Fernández et al. prepared a mesoporous silica-based nanocarrier loaded with dexamethasone and capped with a particular protein to actively target the TNFR1 receptor, which is overexpressed in pro-inflammatory macrophages [ 72 ]. Since the carriers are preferably internalized by these macrophages, the cargo is released in a controlled manner, during enzymatic hydrolysis, thus preventing premature drug release, thanks to the gatekeepers. The targeting talent was tested in vitro with activated macrophages. On the other hand, the therapeutic efficiency was tested in vivo in mouse models. The researchers observed greater therapeutic impacts and fewer adverse side influences than in the case of free dexamethasone. To sum up, dexamethasone-loaded MSN has been effectively developed to actively target the lungs in acute lung injury (ALI), and this result may also be promising in other lung diseases (COPD, asthma) [ 72 ]. Teruel et al. presented a novel approach in oral inflammatory bowel sickness (IBD) therapy, using functionalized magnetic mesoporous silica microparticles [ 75 ].
What drives silica raw material prices?
mesoporous silica 44. Trzeciak K., Chotera-Ouda A., Bak-Sypien I.I., Potrzebowski M.J. Mesoporous silica particles as drug delivery systems - The state of the art in loading techniques and the recent progress in analytical approaches for monitoring these processes. Pharmaceutics. 2021;13:950. doi: 10.3390/pharmaceutics13070950. [ DOI ] [ PMC free post ] [ PubMed ] [ Google Scholar ]
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.